Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma.
Brian Ramnaraign, MD, assistant professor of medicine, Division of Hematology and Oncology, University of Florida College of Medicine, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma (RCC).
Currently, many first-line treatment options are available for use in this patient population, according to Ramnaraign. When choosing among these approaches, is important to determine whether a patient has favorable-, intermediate-, or poor-risk disease, Ramnaraign says.
There are 3 category 1 National Comprehensive Cancer Network recommendations for patients with favorable-risk disease, and 4 recommendations for those with intermediate- and poor-risk disease, Ramnaraign explains.
For patients with poor- or immediate-risk disease, possible treatment strategies include dual immunotherapy regimens or immunotherapies in combination with TKIs. For those with favorable-risk disease, immunotherapy/TKI combinations are often utilized, Ramnaraign concludes.